Stay updated with breaking news from Important Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr 1, 2024--
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents...
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in...